RT Journal Article
SR Electronic
T1 Machine Learning for Identifying Data-Driven Subphenotypes of Incident Post-Acute SARS-CoV-2 Infection Conditions with Large Scale Electronic Health Records: Findings from the RECOVER Initiative
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.21.22275412
DO 10.1101/2022.05.21.22275412
A1 Zhang, Hao
A1 Zang, Chengxi
A1 Xu, Zhenxing
A1 Zhang, Yongkang
A1 Xu, Jie
A1 Bian, Jiang
A1 Morozyuk, Dmitry
A1 Khullar, Dhruv
A1 Zhang, Yiye
A1 Nordvig, Anna S.
A1 Schenck, Edward J.
A1 Shenkman, Elizabeth A.
A1 Rothman, Russel L.
A1 Block, Jason P.
A1 Lyman, Kristin
A1 Weiner, Mark G.
A1 Carton, Thomas W.
A1 Wang, Fei
A1 Kaushal, Rainu
YR 2022
UL http://medrxiv.org/content/early/2022/06/08/2022.05.21.22275412.abstract
AB The post-acute sequelae of SARS-CoV-2 infection (PASC) refers to a broad spectrum of symptoms and signs that are persistent, exacerbated, or newly incident in the post-acute SARS-CoV-2 infection period of COVID-19 patients. Most studies have examined these conditions individually without providing concluding evidence on co-occurring conditions. To answer this question, this study leveraged electronic health records (EHRs) from two large clinical research networks from the national Patient-Centered Clinical Research Network (PCORnet) and investigated patients’ newly incident diagnoses that appeared within 30 to 180 days after a documented SARS-CoV-2 infection. Through machine learning, we identified four reproducible subphenotypes of PASC dominated by blood and circulatory system, respiratory, musculoskeletal and nervous system, and digestive system problems, respectively. We also demonstrated that these subphenotypes were associated with distinct patterns of patient demographics, underlying conditions present prior to SARS-CoV-2 infection, acute infection phase severity, and use of new medications in the post-acute period. Our study provides novel insights into the heterogeneity of PASC and can inform stratified decision-making in the treatment of COVID-19 patients with PASC conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Institutes of Health (NIH) Agreement OTA OT2HL161847 (contract number HER-01-21) as part of the Researching COVID to Enhance Recovery (RECOVER) research program Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Weill Cornell Medicine gave ethical approval for this work; IRB of the University of Florida gave ethical approval for this work;I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding authors